|
Volumn 9, Issue 5, 2002, Pages 441-447
|
Myotonic dystrophy type 2
|
Author keywords
Multisystem disease; Muscular dystrophy; Myopathy; Myotonia; Neuromuscular disorder
|
Indexed keywords
BARBITURIC ACID DERIVATIVE;
BENZODIAZEPINE DERIVATIVE;
CARBAMAZEPINE;
CORTICOSTEROID;
MEXILETINE;
NEUROMUSCULAR DEPOLARIZING AGENT;
NONSTEROID ANTIINFLAMMATORY AGENT;
OPIATE DERIVATIVE;
PHENYTOIN;
QUININE SULFATE;
BRAIN DYSFUNCTION;
CATARACT;
CHROMOSOME 3Q;
CLINICAL FEATURE;
DISEASE CLASSIFICATION;
DNA DETERMINATION;
ENDOCRINE DISEASE;
GENE;
GENE FREQUENCY;
GENE MUTATION;
GENETIC COUNSELING;
HEART DISEASE;
HUMAN;
INTRON;
LABORATORY TEST;
MORBIDITY;
MUSCLE ATROPHY;
MUSCLE WEAKNESS;
MYOTONIA;
MYOTONIC DYSTROPHY;
MYOTONIC DYSTROPHY TYPE 2;
NEUROMUSCULAR DISEASE;
NONHUMAN;
PATHOGENESIS;
PHENOTYPE;
PRIORITY JOURNAL;
PROGNOSIS;
RESPIRATION DEPRESSION;
REVIEW;
ZNF9 GENE;
ANTI-INFLAMMATORY AGENTS;
HUMANS;
MUSCLE, SKELETAL;
MUTATION;
MYOTONIC DYSTROPHY;
PHENOTYPE;
RNA-BINDING PROTEINS;
|
EID: 0036049412
PISSN: 13515101
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1468-1331.2002.00453.x Document Type: Review |
Times cited : (52)
|
References (47)
|